Eltromag 25 Mg Tablets - Drug Type: Health Supplements

Introduction

Eltrombopag 25 mg Tablets are prescription medicines used to treat certain conditions associated with low platelet counts (thrombocytopenia). Eltrombopag is a thrombopoietin receptor agonist (TPO-RA) that stimulates platelet production in the bone marrow, helping increase platelet counts and reduce the risk of bleeding in eligible patients.

Composition

• 
  Active Ingredient: Eltrombopag
  


• 
  Strength: 25 mg
  


• 
  Dosage Form: Film-Coated Tablet
  


• 
  Therapeutic Class: Thrombopoietin Receptor Agonist (TPO-RA)
  

Uses

• 
  Treatment of immune thrombocytopenia (ITP) in patients who have had an insufficient response to other treatments.
  


• 
  Treatment of thrombocytopenia in adults with chronic hepatitis C when low platelet counts interfere with interferon-based therapy, where applicable.
  


• 
  Treatment of severe aplastic anemia in eligible patients, according to the applicable treatment regimen.
  


• 
  Helps stimulate platelet production and increase platelet counts.
  

Dosage

Take Eltrombopag 25 mg exactly as prescribed by your healthcare provider. The dosage varies according to the underlying condition, platelet response, age, liver function, and other factors.

Eltrombopag should generally be taken on an empty stomach, at least 1 hour before or 2 hours after food. It should also be separated from products containing polyvalent cations such as calcium, iron, magnesium, aluminum, selenium, or zinc, which can reduce absorption.

Swallow the tablet whole with water. Do not change the dose or discontinue treatment without medical advice.

Precautions

• 
  Use only under the supervision of a qualified healthcare professional.
  


• 
  Regular monitoring of platelet counts and liver function tests is required.
  


• 
  Eltrombopag may cause liver toxicity, blood clots, and excessive increases in platelet counts.
  


• 
  Inform your doctor if you have liver disease, a history of blood clots, or other significant medical conditions.
  


• 
  Eltrombopag may cause or worsen cataracts in some patients; report changes in vision.
  


• 
  Avoid taking it together with calcium-rich foods, mineral supplements, antacids, or other polyvalent-cation-containing products unless appropriate spacing is maintained.
  


• 
  Tell your healthcare provider about all prescription medicines, over-the-counter drugs, vitamins, minerals, and herbal supplements.
  


• 
  Report symptoms such as chest pain, sudden shortness of breath, leg swelling, severe abdominal pain, unusual bleeding, or vision changes promptly.
  


• 
  Do not alter or discontinue treatment without medical advice.
  

Storage

Store at room temperature in a cool, dry place away from direct sunlight, excessive heat, and moisture. Keep the tablets in their original packaging and out of reach of children.

Conclusion

Eltrombopag 25 mg Tablets are thrombopoietin receptor agonists used to increase platelet production in eligible patients with conditions such as immune thrombocytopenia, hepatitis C-associated thrombocytopenia, and severe aplastic anemia. Treatment requires individualized dosing and regular monitoring of platelet counts and liver function to maintain an appropriate platelet response while minimizing complications.